Study of of Max-40279-01 for advanced gastric cancer or gastroesophageal junction cancer

The research company Maxinovel Pty., Ltd is conducting the Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer.

This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.

It is planned to include 30 participants.

Actual study start date is June 2022. The researchers expect to complete the study by December 2023.

One primary outcome measure is Objective response rate (ORR).

Further details can be found here https://ichgcp.net/clinical-trials-registry/NCT05395780.